{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,14]],"date-time":"2026-11-14T06:55:30Z","timestamp":1794639330699,"version":"4.9.1"},"reference-count":52,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2025,7,28]],"date-time":"2025-07-28T00:00:00Z","timestamp":1753660800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Neurosci."],"abstract":"<jats:p>The mechanistic target of rapamycin (mTOR) pathway plays an important role in regulating multiple cellular processes, including cell growth, autophagy, proliferation, protein synthesis, and lipid synthesis, among others. Given the central role of this pathway in multiple cellular processes, it is not surprising that mTOR pathway dysregulation is a key mechanism underlying several neurological disorders, including Tuberous Sclerosis Complex (TSC). TSC patients typically present with pathogenic variants in the <jats:italic>TSC1<\/jats:italic> or <jats:italic>TSC2<\/jats:italic> genes, which encode proteins forming a complex that plays an important role in modulating mTOR activity. We previously reported cellular and functional deficits in induced pluripotent stem cell (iPSC)-derived neurons from TSC patients. These deficits were reversed by inhibiting mTOR activity using rapamycin treatment, revealing the role of mTOR signaling in the regulation of cell morphology and hyperexcitability phenotypes in TSC patient-derived neurons. However, chronic rapamycin treatment inhibits both mTORC1 and mTORC2 activity and its clinical use is associated with significant side effects. With the development of novel mTORC1-selective compounds, we aimed to assess whether selective inhibition of mTORC1 likewise reversed the cellular and functional deficits found in TSC patient-derived neurons. Our results indicate that the novel, selective mTORC1 inhibitors nearly fully reversed the cellular and functional deficits of <jats:italic>TSC2<\/jats:italic><jats:sup>\u2013\/<\/jats:sup><jats:italic><jats:sup>\u2013<\/jats:sup><\/jats:italic> iPSC-derived neurons in a fashion and magnitude similar to rapamycin, as they all reversed and near-normalized their neuronal hyperexcitability and abnormal morphology as compared to the DMSO-treated cells. These data suggest that mTORC1-specific compounds could provide clinical therapeutic benefit similar to rapamycin without the same side effects.<\/jats:p>","DOI":"10.3389\/fnins.2025.1595880","type":"journal-article","created":{"date-parts":[[2025,7,28]],"date-time":"2025-07-28T13:31:17Z","timestamp":1753709477000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":4,"title":["mTORC1-selective inhibitors rescue cellular phenotypes in TSC iPSC-derived neurons"],"prefix":"10.3389","volume":"19","author":[{"given":"Elizabeth D.","family":"Buttermore","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gayathri Rajaram","family":"Srinivasan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hellen","family":"Jumo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amanda C.","family":"Swanson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Benjamin","family":"O\u2019Kelly","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nina R.","family":"Makhortova","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mustafa","family":"Sahin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stelios T.","family":"Tzannis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2025,7,28]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"16","DOI":"10.1186\/s13229-020-0320-2","article-title":"Recent advances in human stem cell-based modeling of Tuberous Sclerosis Complex.","volume":"11","author":"Afshar Saber","year":"2020","journal-title":"Mol Autism"},{"key":"B2","doi-asserted-by":"publisher","first-page":"e7124","DOI":"10.1371\/journal.pone.0007124","article-title":"Screen for chemical modulators of autophagy reveals novel therapeutic inhibitors of mTORC1 signaling.","volume":"4","author":"Balgi","year":"2009","journal-title":"PLoS One"},{"key":"B3","doi-asserted-by":"publisher","first-page":"510","DOI":"10.1016\/j.neuron.2013.03.017","article-title":"Excitatory\/inhibitory synaptic imbalance leads to hippocampal hyperexcitability in mouse models of tuberous sclerosis.","volume":"78","author":"Bateup","year":"2013","journal-title":"Neuron"},{"key":"B4","doi-asserted-by":"publisher","first-page":"90","DOI":"10.1089\/adt.2009.9996","article-title":"AlphaLISA immunoassay platform- the \u201cno-wash\u201d high-throughput alternative to ELISA.","volume":"7","author":"Bielefeld-Sevigny","year":"2009","journal-title":"Assay Drug Dev. Technol."},{"key":"B5","doi-asserted-by":"publisher","first-page":"e0180939","DOI":"10.1371\/journal.pone.0180939","article-title":"Everolimus long-term use in patients with tuberous sclerosis complex: Four-year update of the EXIST-2 study.","volume":"12","author":"Bissler","year":"2017","journal-title":"PLoS One"},{"key":"B6","doi-asserted-by":"publisher","first-page":"17414","DOI":"10.1073\/pnas.0809136105","article-title":"Rapamycin differentially inhibits S6Ks and 4E-BP1 to mediate cell-type-specific repression of mRNA translation.","volume":"105","author":"Choo","year":"2008","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"B7","doi-asserted-by":"publisher","first-page":"86","DOI":"10.1016\/j.celrep.2016.02.090","article-title":"mTORC1 inhibition corrects neurodevelopmental and synaptic alterations in a human stem cell model of tuberous sclerosis.","volume":"15","author":"Costa","year":"2016","journal-title":"Cell Rep."},{"key":"B8","doi-asserted-by":"publisher","first-page":"827","DOI":"10.1523\/JNEUROSCI.1354-22.2022","article-title":"mTORC2 inhibition improves morphological effects of PTEN Loss, but does not correct synaptic dysfunction or prevent seizures.","volume":"43","author":"Cullen","year":"2023","journal-title":"J. Neurosci."},{"key":"B9","doi-asserted-by":"publisher","first-page":"3077","DOI":"10.1038\/s41380-025-02916-2","article-title":"Phenotypic rescue via mTOR inhibition in neuron-specific Pten knockout mice reveals AKT and mTORC1-site specific changes.","volume":"30","author":"D\u2019Amore","year":"2025","journal-title":"Mol. Psychiatry"},{"key":"B10","doi-asserted-by":"publisher","first-page":"114173","DOI":"10.1016\/j.celrep.2024.114173","article-title":"Synergistic hyperactivation of both mTORC1 and mTORC2 underlies the neural abnormalities of PTEN-deficient human neurons and cortical organoids.","volume":"43","author":"Dhaliwal","year":"2024","journal-title":"Cell Rep."},{"key":"B11","doi-asserted-by":"publisher","first-page":"107780","DOI":"10.1016\/j.celrep.2020.107780","article-title":"Phenotypic screen with TSC-deficient neurons reveals heat-shock machinery as a druggable pathway for mtORC1 and reduced cilia.","volume":"31","author":"Di Nardo","year":"2020","journal-title":"Cell Rep."},{"key":"B12","doi-asserted-by":"publisher","first-page":"2162","DOI":"10.1016\/j.celrep.2016.10.051","article-title":"Impaired mitochondrial dynamics and mitophagy in neuronal models of tuberous sclerosis complex.","volume":"17","author":"Ebrahimi-Fakhari","year":"2016","journal-title":"Cell Rep."},{"key":"B13","doi-asserted-by":"publisher","first-page":"1926","DOI":"10.1101\/gad.1212704","article-title":"Upstream and downstream of mTOR.","volume":"18","author":"Hay","year":"2004","journal-title":"Genes Dev."},{"key":"B14","doi-asserted-by":"publisher","first-page":"4104","DOI":"10.1128\/MCB.00289-08","article-title":"The TSC1-TSC2 complex is required for proper activation of mTOR complex 2.","volume":"28","author":"Huang","year":"2008","journal-title":"Mol. Cell Biol."},{"key":"B15","doi-asserted-by":"publisher","first-page":"179","DOI":"10.1042\/BJ20080281","article-title":"The TSC1-TSC2 complex: A molecular switchboard controlling cell growth.","volume":"412","author":"Huang","year":"2008","journal-title":"Biochem. J."},{"key":"B16","doi-asserted-by":"publisher","first-page":"217","DOI":"10.1042\/BST0370217","article-title":"A complex interplay between Akt, TSC2 and the two mTOR complexes.","volume":"37","author":"Huang","year":"2009","journal-title":"Biochem. Soc. Trans."},{"key":"B17","doi-asserted-by":"publisher","first-page":"e1213","DOI":"10.1016\/j.chembiol.2019.05.009","article-title":"Discovery of small-molecule selective mTORC1 inhibitors via direct inhibition of glucose transporters.","volume":"26","author":"Kang","year":"2019","journal-title":"Cell Chem. Biol."},{"key":"B18","doi-asserted-by":"publisher","first-page":"1236566","DOI":"10.1126\/science.1236566","article-title":"mTORC1 phosphorylation sites encode their sensitivity to starvation and rapamycin.","volume":"341","author":"Kang","year":"2013","journal-title":"Science"},{"key":"B19","doi-asserted-by":"publisher","first-page":"4665","DOI":"10.1038\/s41467-022-31961-6","article-title":"Raptor downregulation rescues neuronal phenotypes in mouse models of Tuberous Sclerosis Complex.","volume":"13","author":"Karalis","year":"2022","journal-title":"Nat. Commun."},{"key":"B20","doi-asserted-by":"publisher","first-page":"877","DOI":"10.1002\/acn3.494","article-title":"Everolimus for treatment of tuberous sclerosis complex-associated neuropsychiatric disorders.","volume":"4","author":"Krueger","year":"2017","journal-title":"Ann. Clin. Transl. Neurol."},{"key":"B21","doi-asserted-by":"publisher","first-page":"a025924","DOI":"10.1101\/cshperspect.a025924","article-title":"Inhibition of the mechanistic target of Rapamycin (mTOR)-Rapamycin and beyond.","volume":"6","author":"Lamming","year":"2016","journal-title":"Cold Spring Harb. Perspect. Med."},{"key":"B22","doi-asserted-by":"publisher","first-page":"1638","DOI":"10.1126\/science.1215135","article-title":"Rapamycin-induced insulin resistance is mediated by mTORC2 loss and uncoupled from longevity.","volume":"335","author":"Lamming","year":"2012","journal-title":"Science"},{"key":"B23","doi-asserted-by":"publisher","first-page":"883","DOI":"10.1016\/j.stemcr.2017.02.020","article-title":"Abnormal neural progenitor cells differentiated from induced pluripotent stem cells partially mimicked development of TSC2 neurological abnormalities.","volume":"8","author":"Li","year":"2017","journal-title":"Stem Cell Rep."},{"key":"B24","doi-asserted-by":"publisher","first-page":"2118","DOI":"10.1016\/j.stemcr.2021.07.006","article-title":"NGN2 induces diverse neuron types from human pluripotency.","volume":"16","author":"Lin","year":"2021","journal-title":"Stem Cell Rep."},{"key":"B25","doi-asserted-by":"publisher","first-page":"275","DOI":"10.1016\/j.neuron.2014.09.034","article-title":"The neurology of mTOR.","volume":"84","author":"Lipton","year":"2014","journal-title":"Neuron"},{"key":"B26","doi-asserted-by":"publisher","first-page":"548","DOI":"10.1038\/s41467-018-03035-z","article-title":"A small molecule inhibitor of Rheb selectively targets mTORC1 signaling.","volume":"9","author":"Mahoney","year":"2018","journal-title":"Nat. Commun."},{"key":"B27","doi-asserted-by":"publisher","first-page":"e51440","DOI":"10.7554\/eLife.51440","article-title":"Genetic inactivation of mTORC1 or mTORC2 in neurons reveals distinct functions in glutamatergic synaptic transmission.","volume":"9","author":"McCabe","year":"2020","journal-title":"Elife"},{"key":"B28","doi-asserted-by":"publisher","first-page":"fcab222","DOI":"10.1093\/braincomms\/fcab222","article-title":"Epilepsy in the mTORopathies: Opportunities for precision medicine.","volume":"3","author":"Moloney","year":"2021","journal-title":"Brain Commun."},{"key":"B29","doi-asserted-by":"publisher","first-page":"3341","DOI":"10.1111\/ene.15975","article-title":"Everolimus precision therapy for the GATOR1-related epilepsies: A case series.","volume":"30","author":"Moloney","year":"2023","journal-title":"Eur. J. Neurol."},{"key":"B30","doi-asserted-by":"publisher","first-page":"951","DOI":"10.2147\/TCRM.S145630","article-title":"Everolimus for the treatment of refractory seizures associated with tuberous sclerosis complex (TSC): Current perspectives.","volume":"15","author":"Overwater","year":"2019","journal-title":"Ther. Clin. Risk Manag."},{"key":"B31","doi-asserted-by":"publisher","first-page":"608","DOI":"10.1016\/j.tins.2020.05.004","article-title":"Neurodevelopmental disorders: From genetics to functional pathways.","volume":"43","author":"Parenti","year":"2020","journal-title":"Trends Neurosci."},{"key":"B32","doi-asserted-by":"publisher","first-page":"1052","DOI":"10.1038\/s41467-017-00933-6","article-title":"Variation in a range of mTOR-related genes associates with intracranial volume and intellectual disability.","volume":"8","author":"Reijnders","year":"2017","journal-title":"Nat. Commun."},{"key":"B33","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1590\/1678-4685-GMB-2015-0321","article-title":"TSC1 and TSC2 gene mutations and their implications for treatment in Tuberous Sclerosis Complex: A review.","volume":"40","author":"Rosset","year":"2017","journal-title":"Genet. Mol. Biol."},{"key":"B34","doi-asserted-by":"publisher","first-page":"159","DOI":"10.1016\/j.molcel.2006.03.029","article-title":"Prolonged rapamycin treatment inhibits mTORC2 assembly and Akt\/PKB.","volume":"22","author":"Sarbassov","year":"2006","journal-title":"Mol. Cell"},{"key":"B35","doi-asserted-by":"publisher","first-page":"1098","DOI":"10.1126\/science.1106148","article-title":"Phosphorylation and regulation of Akt\/PKB by the rictor-mTOR complex.","volume":"307","author":"Sarbassov","year":"2005","journal-title":"Science"},{"key":"B36","doi-asserted-by":"publisher","first-page":"3194","DOI":"10.1038\/s41467-019-11174-0","article-title":"A novel rapamycin analog is highly selective for mTORC1 in vivo.","volume":"10","author":"Schreiber","year":"2019","journal-title":"Nat. Commun."},{"key":"B37","doi-asserted-by":"publisher","first-page":"3393","DOI":"10.1093\/hmg\/ddac111","article-title":"A randomized controlled trial of everolimus for neurocognitive symptoms in PTEN hamartoma tumor syndrome.","volume":"31","author":"Srivastava","year":"2022","journal-title":"Hum. Mol. Genet."},{"key":"B38","doi-asserted-by":"publisher","first-page":"e13073","DOI":"10.7554\/eLife.13073","article-title":"A deleterious Nav1.1 mutation selectively impairs telencephalic inhibitory neurons derived from Dravet Syndrome patients.","volume":"5","author":"Sun","year":"2016","journal-title":"Elife"},{"key":"B39","doi-asserted-by":"publisher","first-page":"2167","DOI":"10.1038\/s41380-018-0018-4","article-title":"Purkinje cells derived from TSC patients display hypoexcitability and synaptic deficits associated with reduced FMRP levels and reversed by rapamycin.","volume":"23","author":"Sundberg","year":"2018","journal-title":"Mol. Psychiatry"},{"key":"B40","doi-asserted-by":"publisher","first-page":"112","DOI":"10.1016\/j.neuroscience.2016.11.017","article-title":"Molecular neurobiology of mTOR.","volume":"341","author":"Switon","year":"2017","journal-title":"Neuroscience"},{"key":"B41","doi-asserted-by":"publisher","first-page":"437","DOI":"10.1097\/CAD.0000000000000207","article-title":"Complications of mammalian target of rapamycin inhibitor anticancer treatment among patients with tuberous sclerosis complex are common and occasionally life-threatening.","volume":"26","author":"Trelinska","year":"2015","journal-title":"Anticancer Drugs"},{"key":"B42","doi-asserted-by":"publisher","first-page":"30240","DOI":"10.1074\/jbc.M112.374405","article-title":"Mammalian target of rapamycin complex 1 (mTORC1) and 2 (mTORC2) control the dendritic arbor morphology of hippocampal neurons.","volume":"287","author":"Urbanska","year":"2012","journal-title":"J. Biol. Chem."},{"key":"B43","doi-asserted-by":"publisher","first-page":"1746","DOI":"10.3390\/genes12111746","article-title":"Translating the Role of mTOR- and RAS-associated signalopathies in autism spectrum disorder: Models, mechanisms and treatment.","volume":"12","author":"Vasic","year":"2021","journal-title":"Genes"},{"key":"B44","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3389\/fnmol.2014.00001","article-title":"Loss of mTOR repressors Tsc1 or Pten has divergent effects on excitatory and inhibitory synaptic transmission in single hippocampal neuron cultures.","volume":"7","author":"Weston","year":"2014","journal-title":"Front. Mol. Neurosci."},{"key":"B45","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1146\/annurev-neuro-080317-061747","article-title":"Abnormal mTOR activation in autism.","volume":"41","author":"Winden","year":"2018","journal-title":"Annu. Rev. Neurosci."},{"key":"B46","doi-asserted-by":"publisher","first-page":"112838","DOI":"10.1016\/j.celrep.2023.112838","article-title":"Increased degradation of FMRP contributes to neuronal hyperexcitability in tuberous sclerosis complex.","volume":"42","author":"Winden","year":"2023","journal-title":"Cell Rep."},{"key":"B47","doi-asserted-by":"publisher","first-page":"9294","DOI":"10.1523\/JNEUROSCI.0642-19.2019","article-title":"Biallelic Mutations in TSC2 lead to abnormalities associated with cortical tubers in human iPSC-derived neurons.","volume":"39","author":"Winden","year":"2019","journal-title":"J. Neurosci."},{"key":"B48","doi-asserted-by":"publisher","first-page":"1244","DOI":"10.1002\/glia.22326","article-title":"Tuberous sclerosis and epilepsy: Role of astrocytes.","volume":"60","author":"Wong","year":"2012","journal-title":"Glia"},{"key":"B49","doi-asserted-by":"publisher","first-page":"621","DOI":"10.1038\/nmeth.4291","article-title":"Generation of pure GABAergic neurons by transcription factor programming.","volume":"14","author":"Yang","year":"2017","journal-title":"Nat. Methods"},{"key":"B50","doi-asserted-by":"publisher","first-page":"1524577","DOI":"10.3389\/fnins.2024.1524577","article-title":"Harnessing the potential of human induced pluripotent stem cells, functional assays and machine learning for neurodevelopmental disorders.","volume":"18","author":"Yang","year":"2024","journal-title":"Front. Neurosci."},{"key":"B51","doi-asserted-by":"publisher","first-page":"R880","DOI":"10.1016\/j.cub.2013.08.030","article-title":"Rapamycin resistance: mTORC1 substrates hold some of the answers.","volume":"23","author":"Yoon","year":"2013","journal-title":"Curr. Biol."},{"key":"B52","doi-asserted-by":"publisher","first-page":"785","DOI":"10.1016\/j.neuron.2013.05.029","article-title":"Rapid single-step induction of functional neurons from human pluripotent stem cells.","volume":"78","author":"Zhang","year":"2013","journal-title":"Neuron"}],"container-title":["Frontiers in Neuroscience"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fnins.2025.1595880\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,7,28]],"date-time":"2025-07-28T13:31:18Z","timestamp":1753709478000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fnins.2025.1595880\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,7,28]]},"references-count":52,"alternative-id":["10.3389\/fnins.2025.1595880"],"URL":"https:\/\/doi.org\/10.3389\/fnins.2025.1595880","relation":{"has-part":[{"id-type":"doi","id":"https:\/\/doi.org\/10.3389\/fnins.2025.1595880.s001","asserted-by":"subject"},{"id-type":"doi","id":"https:\/\/doi.org\/10.3389\/fnins.2025.1595880.s002","asserted-by":"subject"},{"id-type":"doi","id":"https:\/\/doi.org\/10.3389\/fnins.2025.1595880.s003","asserted-by":"subject"}]},"ISSN":["1662-453X"],"issn-type":[{"value":"1662-453X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,7,28]]},"article-number":"1595880"}}